208 related articles for article (PubMed ID: 24795781)
21. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
22. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
Stordal B; Hamon M; McEneaney V; Roche S; Gillet JP; O'Leary JJ; Gottesman M; Clynes M
PLoS One; 2012; 7(7):e40717. PubMed ID: 22792399
[TBL] [Abstract][Full Text] [Related]
23. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
24. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
Tieszen CR; Goyeneche AA; Brandhagen BN; Ortbahn CT; Telleria CM
BMC Cancer; 2011 May; 11():207. PubMed ID: 21619605
[TBL] [Abstract][Full Text] [Related]
25. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells.
Li S; Yang L; Wang J; Liang F; Chang B; Gu H; Wang H; Yang G; Chen Y
Oncotarget; 2016 Aug; 7(35):57145-57159. PubMed ID: 27494891
[TBL] [Abstract][Full Text] [Related]
27. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
28. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
29. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
Metzinger DS; Taylor DD; Gercel-Taylor C
Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
31. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.
Lin YH; Chen BY; Lai WT; Wu SF; Guh JH; Cheng AL; Hsu LC
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jan; 388(1):19-31. PubMed ID: 25164962
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
33. Antiprogestins and iatrogenic glucocorticoid resistance.
Koper JW; Molijn GJ; van Uffelen CJ; Stigter E; Lamberts SW
Life Sci; 1997; 60(9):617-24. PubMed ID: 9048964
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
35. The possible use of antiprogestins for contraception.
Bygdeman M; Danielsson KG; Swahn ML
Acta Obstet Gynecol Scand Suppl; 1997; 164():75-7. PubMed ID: 9225644
[TBL] [Abstract][Full Text] [Related]
36. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of mifepristone (RU486) in refractory ovarian cancer.
Rocereto TF; Saul HM; Aikins JA; Paulson J
Gynecol Oncol; 2000 Jun; 77(3):429-32. PubMed ID: 10831354
[TBL] [Abstract][Full Text] [Related]
38. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells].
Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY
Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028
[TBL] [Abstract][Full Text] [Related]
39. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
40. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
Zhang R; Yang X; Roque DM; Li C; Lin J
PLoS One; 2021; 16(4):e0240145. PubMed ID: 33909625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
